UNLABELLED: Whole-body PET/CT was used to characterize the radiation dosimetry of (11)C-DPA-713, a specific PET ligand for the assessment of translocator protein. METHODS: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of (11)C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. RESULTS: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 × 10(-2) mSv/MBq (7.43 × 10(-2) rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for (11)C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). CONCLUSION: (11)C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other (11)C-labeled PET tracers.
UNLABELLED: Whole-body PET/CT was used to characterize the radiation dosimetry of (11)C-DPA-713, a specific PET ligand for the assessment of translocator protein. METHODS: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of (11)C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. RESULTS: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 × 10(-2) mSv/MBq (7.43 × 10(-2) rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for (11)C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). CONCLUSION:(11)C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other (11)C-labeled PET tracers.
Authors: Vassilios Papadopoulos; Mario Baraldi; Tomás R Guilarte; Thomas B Knudsen; Jean-Jacques Lacapère; Peter Lindemann; Michael D Norenberg; David Nutt; Abraham Weizman; Ming-Rong Zhang; Moshe Gavish Journal: Trends Pharmacol Sci Date: 2006-07-05 Impact factor: 14.819
Authors: David R Owen; Owain W Howell; Sac-Pham Tang; Lisa A Wells; Idriss Bennacef; Mats Bergstrom; Roger N Gunn; Eugenii A Rabiner; Martin R Wilkins; Richard Reynolds; Paul M Matthews; Christine A Parker Journal: J Cereb Blood Flow Metab Date: 2010-04-28 Impact factor: 6.200
Authors: Michelle L James; Roger R Fulton; David J Henderson; Stefan Eberl; Steven R Meikle; Sally Thomson; Robin D Allan; Frederic Dolle; Michael J Fulham; Michael Kassiou Journal: Bioorg Med Chem Date: 2005-07-20 Impact factor: 3.641
Authors: Jussi Hirvonen; Anne Roivainen; Jere Virta; Semi Helin; Kjell Någren; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-28 Impact factor: 9.236
Authors: Jennifer M Coughlin; Yuchuan Wang; Shuangchao Ma; Chen Yue; Pearl K Kim; Ashley V Adams; Heidi V Roosa; Kenneth L Gage; Marigo Stathis; Rana Rais; Camilo Rojas; Jennifer L McGlothan; Crystal C Watkins; Ned Sacktor; Tomas R Guilarte; Yun Zhou; Akira Sawa; Barbara S Slusher; Brian Caffo; Michael Kassiou; Christopher J Endres; Martin G Pomper Journal: J Neurovirol Date: 2014-02-25 Impact factor: 2.643
Authors: DeLisa Fairweather; Michael J Coronado; Amanda E Garton; Jennifer L Dziedzic; Adriana Bucek; Leslie T Cooper; Jessica E Brandt; Fatima S Alikhan; Haofan Wang; Christopher J Endres; Judy Choi; Martin G Pomper; Tomás R Guilarte Journal: J Cardiovasc Transl Res Date: 2014-01-09 Impact factor: 4.132
Authors: Catherine A Foss; Liansheng Liu; Ronnie C Mease; Haofan Wang; Pankaj Pasricha; Martin G Pomper Journal: J Nucl Med Date: 2017-05-18 Impact factor: 10.057
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare Journal: J Neuroimmune Pharmacol Date: 2019-12-13 Impact factor: 4.147
Authors: Bin Liu; Kevin X Le; Mi-Ae Park; Shuyan Wang; Anthony P Belanger; Shipra Dubey; Jeffrey L Frost; Peter Holton; Vladimir Reiser; Paul A Jones; William Trigg; Marcelo F Di Carli; Cynthia A Lemere Journal: J Neurosci Date: 2015-11-25 Impact factor: 6.167